NOVEL APPLICATION OF NANOTECHNOLOGY AND SENSOR TECHNOLOGIES FOR EX-VIVO DIAGNOSTICS
First Claim
Patent Images
1. A method for detecting ex vivo a target analyte/biomarker comprising:
- (a) collecting a sample of bodily fluid in a container, wherein the container comprises the sample of bodily fluid and a headspace;
(b) mixing ex vivo to the bodily fluid in the container a nanostucture-based assembly that comprises a surrogate marker where the surrogate marker is released from the nanostructure-based assembly in the presence of a target analyte/biomarker;
(c) applying sensor technology to the head space or bodily fluid sample in the container, which contains the mixture of nanostructure-based assembly and bodily fluid sample in the container, wherein (he sensor technology can detect a surrogate marker released from tile nanostructure-based assembly in the container; and
(d) determining whether the sample contains the target analyte/biomarker by using the sensor technology to detect the presence of the surrogate marker, wherein detection of the surrogate marker indicates the presence of the target analyte/biomarker in the sample of bodily fluid in the container.
3 Assignments
0 Petitions
Accused Products
Abstract
Systems and methods for the ex vivo diagnostic analysis of samples of bodily fluids, including exhaled breath and blood. The present invention uses nanostructure-based assemblies in combination with sensor technology to provide an efficient and accurate means for identifying the presence of a target analyte/biomarker in a sample of bodily fluid. In a preferred embodiment, the nanostructure-based assemblies of the present invention include detecting means such as RNA oligonucleotide chains or “aptamers” and releasable surrogate markers such as DMSO.
118 Citations
12 Claims
-
1. A method for detecting ex vivo a target analyte/biomarker comprising:
-
(a) collecting a sample of bodily fluid in a container, wherein the container comprises the sample of bodily fluid and a headspace;
(b) mixing ex vivo to the bodily fluid in the container a nanostucture-based assembly that comprises a surrogate marker where the surrogate marker is released from the nanostructure-based assembly in the presence of a target analyte/biomarker;
(c) applying sensor technology to the head space or bodily fluid sample in the container, which contains the mixture of nanostructure-based assembly and bodily fluid sample in the container, wherein (he sensor technology can detect a surrogate marker released from tile nanostructure-based assembly in the container; and
(d) determining whether the sample contains the target analyte/biomarker by using the sensor technology to detect the presence of the surrogate marker, wherein detection of the surrogate marker indicates the presence of the target analyte/biomarker in the sample of bodily fluid in the container. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
-
-
12-24. -24. (canceled)
Specification